Is IMNM a Buy? What to Consider in 2026
Short answer
The bull case for Immunome (IMNM) rests on Varegacestat FDA decision and launch: The submitted NDA for varegacestat in desmoid tumors is the single largest near-term driver. Revenue (FY2025) is ~$7M. If you believe that thesis holds, the real questions become position sizing and overlap, not timing. The main risk to that view: As a clinical-stage biotech, Immunome is exposed to substantial binary risk: the FDA could delay, restrict, or reject varegacestat, and any label or safety concern would materially reset the stock. Whether IMNM is a buy comes down to whether you believe the thesis. This is informational, not a recommendation, and Walnut is not an investment adviser.
Immunome, Inc. is a Nasdaq-listed, clinical-stage targeted-oncology company developing cancer therapies. Its lead asset is varegacestat, a once-daily oral gamma secretase inhibitor for adults with progressing desmoid tumors; the company submitted a New Drug Application to the U.S. FDA in April 2026, backed by the Phase 3 RINGSIDE trial that showed an ~84% reduction in the risk of disease progression or death and a ~56% confirmed objective response rate versus ~9% for placebo. Behind that lead program sits an antibody-drug-conjugate (ADC) and radiotherapy pipeline, including IM-1021 (a ROR1 ADC), IM-3050 (a FAP-targeted radiotherapy), IM-1617, and additional preclinical candidates. As a pre-commercial developer, Immunome generates only minimal collaboration-related revenue (roughly $7 million in 2025) against large research spending and recurring net losses, so the investment picture is not about earnings today. It is about whether varegacestat wins approval and launches successfully into a market where a rival oral therapy already exists, and whether the broader ADC engine produces additional clinical wins. A cash position of roughly $582.7 million as of March 2026 funds that plan into 2028, but the equity remains a speculative, catalyst-driven biotech.
What's the case for buying IMNM?
1. Varegacestat FDA decision and launch
The submitted NDA for varegacestat in desmoid tumors is the single largest near-term driver. Strong Phase 3 RINGSIDE data (roughly 84% reduction in progression-or-death risk and a ~56% objective response rate) supports the filing, and an approval would turn Immunome into a commercial-stage company. The launch would enter a market where an approved oral competitor already exists.
2. ADC and radiotherapy pipeline
Beyond the lead drug, Immunome is building a pipeline of antibody-drug conjugates and targeted radiotherapies, including IM-1021 (ROR1 ADC), IM-3050 (FAP radiotherapy), and IM-1617. Management has guided to additional IND filings (IM-1340 and IM-1335) through 2026 and beyond. Investors increasingly frame varegacestat as the beachhead and the ADC platform as the longer-term thesis.
3. Strong balance sheet and runway
Cash and equivalents of roughly $582.7 million as of March 31, 2026 give Immunome runway into 2028, which reduces near-term financing pressure. That capital lets the company fund a potential commercial launch and advance multiple clinical programs at once. It does not, however, remove dilution risk if the company raises again to fund growth.
4. Desmoid tumor market opportunity
Desmoid tumors are a rare, locally aggressive soft-tissue condition with limited systemic options, giving a differentiated oral therapy a defined commercial niche. Immunome positions varegacestat on efficacy and tolerability against the incumbent. Success here could also validate the gamma secretase mechanism for adjacent indications.
What are the risks to IMNM?
As a clinical-stage biotech, Immunome is exposed to substantial binary risk: the FDA could delay, restrict, or reject varegacestat, and any label or safety concern would materially reset the stock. The company has minimal product revenue and posts recurring net losses (a net loss of roughly $53.8 million in Q1 2026), so it depends on its cash balance and, potentially, future capital raises that could dilute shareholders. Even with approval, commercial uptake is uncertain because an established oral competitor already serves the desmoid market. Pipeline candidates are early and most drug programs fail in development. The shares are volatile and can move sharply on single trial, regulatory, or insider-selling headlines.
How is IMNM valued? (as of JULY 2026)
Snapshot for IMNM as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Market cap: ~$2.6B
- Share price: ~$23
- Revenue (FY2025): ~$7M
- Cash & equivalents (Mar 2026): ~$582.7M
- Net loss (Q1 2026): ~$53.8M
- R&D expense (Q1 2026): ~$46.4M
Immunome trades on pipeline expectations, not profits, so conventional earnings multiples do not apply to a pre-commercial developer with minimal revenue and ongoing losses. Its roughly $2.6 billion market value largely reflects the market's probability-weighted view of varegacestat approval plus the ADC pipeline. The sizable cash balance funds operations into 2028 but does not by itself justify the valuation.
How do you decide if IMNM is a buy?
Rather than asking whether IMNM is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold IMNM indirectly through an index or sector ETF before adding more.
For the full picture, see the IMNM stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about IMNM against your real portfolio and see your actual exposure before deciding.
The bottom line on IMNM
The bottom line: Immunome's story right now is Varegacestat FDA decision and launch, with revenue (fy2025) at ~$7M. If you believe that narrative continues, the call is about sizing IMNM sensibly and checking overlap with what you own; if you doubt it (the risk: as a clinical-stage biotech, Immunome is exposed to substantial binary risk: the FDA could delay, restrict, or reject varegacestat, and any label or safety concern would materially reset the stock.), it is not for you. Decide from the thesis, not the ticker. Walnut is not an investment adviser.
Build a basket around IMNM with Walnut
Use Immunome as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is IMNM a good stock to buy right now?
+
The case for Immunome right now is Varegacestat FDA decision and launch, with revenue (fy2025) at ~$7M. If you believe that thesis holds, IMNM is a way to own it and the real questions are sizing and overlap, not timing; the main risk to that view is as a clinical-stage biotech, Immunome is exposed to substantial binary risk: the FDA could delay, restrict, or reject varegacestat, and any label or safety concern would materially reset the stock. So it comes down to whether you believe the thesis. Walnut is not an investment adviser and this is not a recommendation.
What does Immunome do?
+
Immunome, Inc.
What are the main risks of IMNM?
+
As a clinical-stage biotech, Immunome is exposed to substantial binary risk: the FDA could delay, restrict, or reject varegacestat, and any label or safety concern would materially reset the stock. The company has minimal product revenue and posts recurring net losses (a net loss of roughly $53.8 million in Q1 2026), so it depends on its cash balance and, potentially, future capital raises that could dilute shareholders. Even with approval, commercial uptake is uncertain because an established oral competitor already serves the desmoid market. Pipeline candidates are early and most drug programs fail in development. The shares are volatile and can move sharply on single trial, regulatory, or insider-selling headlines.
What does Immunome (IMNM) do?
+
Immunome is a clinical-stage targeted-oncology company developing cancer therapies. Its lead drug, varegacestat, is under FDA review for desmoid tumors, and it also runs an antibody-drug-conjugate and radiotherapy pipeline.
Is Immunome profitable?
+
No. As a pre-commercial biotech it generates only minimal revenue (about $7 million in 2025) and posts recurring net losses, including roughly $53.8 million in the first quarter of 2026 as it funds research and development.
What is varegacestat?
+
Varegacestat is Immunome's lead asset, a once-daily oral gamma secretase inhibitor for adults with progressing desmoid tumors. The company submitted a New Drug Application to the FDA in April 2026 after positive Phase 3 RINGSIDE results.
How strong were the varegacestat trial results?
+
In the Phase 3 RINGSIDE trial, varegacestat showed a statistically significant benefit, with roughly an 84% reduction in the risk of disease progression or death and a confirmed objective response rate of about 56% versus about 9% for placebo.
Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell IMNM; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.